Bolt Biotherapeutics
BOLT | NASDAQ
$5.80
-$0.28 (-4.61%)
At close: Nov 16, 2026, 4:00 PM ET
$5.80
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:15 PM ET
Bolt Biotherapeutics Company Profile
Company profile explainedCompany Profile
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| William Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary & Director |
| Grant Yonehiro | Chief Operating Officer & Chief Business Officer |
| Justin Kenkel | Senior Principal Scientist |
| Michael N. Alonso | Senior Vice President of Research |
| Sarah Nemec | Senior Vice President of Finance & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | 4 | Filing |
| Oct 27, 2026 | 3 | Filing |
| Oct 23, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 8-K | Current Report |
| Sep 21, 2026 | 4 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
Bolt Biotherapeutics
| Country | United States |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | William Quinn |
Contact Details
900 Chesapeake Drive Redwood City,
California 94063 United States
Stock Details
| Ticker Symbol | BOLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001641281 |
| CUSIP Number | 097702203 |
| ISIN Number | US0977022039 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove BOLT